These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Accutane risk management program strengthened. FDA Consum; 2002; 36(1):8. PubMed ID: 11881607 [No Abstract] [Full Text] [Related]
24. Contradictory iPledge Requirements Hinder Physician Practice and Patient Care. Pousti BT; Mollanazar NK JAMA Dermatol; 2020 Feb; 156(2):222. PubMed ID: 31895417 [No Abstract] [Full Text] [Related]
25. The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system. Shin J; Cheetham TC; Wong L; Niu F; Kass E; Yoshinaga MA; Sorel M; McCombs JS; Sidney S J Am Acad Dermatol; 2011 Dec; 65(6):1117-25. PubMed ID: 21565419 [TBL] [Abstract][Full Text] [Related]
26. Should isotretinoin be stopped prior to surgery? A critically appraised topic. Wootton CI; Cartwright RP; Manning P; Williams HC Br J Dermatol; 2014 Feb; 170(2):239-44. PubMed ID: 24547720 [No Abstract] [Full Text] [Related]
27. Contradictory iPledge Requirements Hinder Physician Practice and Patient Care-Reply. Tkachenko E; Singer S; Mostaghimi A JAMA Dermatol; 2020 Feb; 156(2):222-223. PubMed ID: 31895435 [No Abstract] [Full Text] [Related]
28. When ads trump evidence: is direct-to-consumer advertising leading practice? Nelson R Am J Nurs; 2007 Oct; 107(10):25-6. PubMed ID: 17895720 [No Abstract] [Full Text] [Related]
29. Mega issues: focusing on the future of dermatology nursing. DNA Board of Directors Dermatol Nurs; 2004 Apr; 16(2):138, 147-8. PubMed ID: 15148897 [TBL] [Abstract][Full Text] [Related]
30. Caring for women with childbearing potential taking teratogenic dermatologic drugs. Guidelines for practice. Perlman SE; Rudy SJ; Pinto C; Townsend-Akpan C J Reprod Med; 2001 Feb; 46(2 Suppl):153-61. PubMed ID: 11255823 [TBL] [Abstract][Full Text] [Related]
31. Holistic nursing achieves ANA specialty status. Evans K Ky Nurse; 2007; 55(2):6. PubMed ID: 17477076 [No Abstract] [Full Text] [Related]
32. FDA embraces risk-management approach. Fox JL Nat Biotechnol; 2003 Oct; 21(10):1120-1. PubMed ID: 14520383 [No Abstract] [Full Text] [Related]
37. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the accutane SMART program. Brinker A; Kornegay C; Nourjah P Arch Dermatol; 2005 May; 141(5):563-9. PubMed ID: 15897377 [TBL] [Abstract][Full Text] [Related]
38. Dermatology Nursing Standards of Clinical Nursing Practice: ensuring a level of competency. Siegel DB; Chussil JT; Hickey CM Dermatol Nurs; 1992 Dec; 4(6):437-42. PubMed ID: 1285999 [TBL] [Abstract][Full Text] [Related]
39. Skin drugs in pregnancy--which ones to use. Guenther L Dermatol Nurs; 1997 Aug; 9(4):233-6, 265; quiz 237-8. PubMed ID: 9325780 [TBL] [Abstract][Full Text] [Related]
40. One voice. Clinton P J Am Acad Nurse Pract; 2008 Apr; 20(4):171. PubMed ID: 18387012 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]